Position paper on tuberculosis screening in patients with imune mediated inflammatory diseases who are candidates for biological therapy

Detalhes bibliográficos
Autor(a) principal: Duarte,Raquel
Data de Publicação: 2012
Outros Autores: Campainha,Sergio, Cotter,José, Rosa,Bruno, Varela,Paulo, Correia,Ana, Canhão,Helena, Fonseca,João Eurico
Tipo de documento: Relatório
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-81782012000600005
Resumo: Chronic immunosuppression is a known risk factor for tuberculosis. Our aim was to reach a consensus on screening and prevention of tuberculosis in patients with immune mediated inflammatory diseases who are candidates to biologic therapy. Methods: Critical appraisal of the literature and expert opinion on immunosuppressive therapies and risk of tuberculosis. Results and conclusion: The currently recommended method for screening is the tuberculin skin test and the interferon gamma assay, after exclusion of active tuberculosis. Positively screened patients should be treated for latent tuberculosis infection. Patients may start biological therapy after 1-2 months, as long as they are strictly adhering to and tolerating their preventive regimen.
id RCAP_1e9121e67d7cd482027a312198f677bf
oai_identifier_str oai:scielo:S0872-81782012000600005
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Position paper on tuberculosis screening in patients with imune mediated inflammatory diseases who are candidates for biological therapyTuberculosis screeningLatent tuberculosisBiological therapiesAnti-TNF drugsImmune mediated inflammatory diseasesChronic immunosuppression is a known risk factor for tuberculosis. Our aim was to reach a consensus on screening and prevention of tuberculosis in patients with immune mediated inflammatory diseases who are candidates to biologic therapy. Methods: Critical appraisal of the literature and expert opinion on immunosuppressive therapies and risk of tuberculosis. Results and conclusion: The currently recommended method for screening is the tuberculin skin test and the interferon gamma assay, after exclusion of active tuberculosis. Positively screened patients should be treated for latent tuberculosis infection. Patients may start biological therapy after 1-2 months, as long as they are strictly adhering to and tolerating their preventive regimen.Sociedade Portuguesa de Gastrenterologia2012-11-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/reporttext/htmlhttp://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-81782012000600005Jornal Português de Gastrenterologia v.19 n.6 2012reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttp://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-81782012000600005Duarte,RaquelCampainha,SergioCotter,JoséRosa,BrunoVarela,PauloCorreia,AnaCanhão,HelenaFonseca,João Euricoinfo:eu-repo/semantics/openAccess2024-02-06T17:09:12Zoai:scielo:S0872-81782012000600005Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T02:21:18.297773Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Position paper on tuberculosis screening in patients with imune mediated inflammatory diseases who are candidates for biological therapy
title Position paper on tuberculosis screening in patients with imune mediated inflammatory diseases who are candidates for biological therapy
spellingShingle Position paper on tuberculosis screening in patients with imune mediated inflammatory diseases who are candidates for biological therapy
Duarte,Raquel
Tuberculosis screening
Latent tuberculosis
Biological therapies
Anti-TNF drugs
Immune mediated inflammatory diseases
title_short Position paper on tuberculosis screening in patients with imune mediated inflammatory diseases who are candidates for biological therapy
title_full Position paper on tuberculosis screening in patients with imune mediated inflammatory diseases who are candidates for biological therapy
title_fullStr Position paper on tuberculosis screening in patients with imune mediated inflammatory diseases who are candidates for biological therapy
title_full_unstemmed Position paper on tuberculosis screening in patients with imune mediated inflammatory diseases who are candidates for biological therapy
title_sort Position paper on tuberculosis screening in patients with imune mediated inflammatory diseases who are candidates for biological therapy
author Duarte,Raquel
author_facet Duarte,Raquel
Campainha,Sergio
Cotter,José
Rosa,Bruno
Varela,Paulo
Correia,Ana
Canhão,Helena
Fonseca,João Eurico
author_role author
author2 Campainha,Sergio
Cotter,José
Rosa,Bruno
Varela,Paulo
Correia,Ana
Canhão,Helena
Fonseca,João Eurico
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Duarte,Raquel
Campainha,Sergio
Cotter,José
Rosa,Bruno
Varela,Paulo
Correia,Ana
Canhão,Helena
Fonseca,João Eurico
dc.subject.por.fl_str_mv Tuberculosis screening
Latent tuberculosis
Biological therapies
Anti-TNF drugs
Immune mediated inflammatory diseases
topic Tuberculosis screening
Latent tuberculosis
Biological therapies
Anti-TNF drugs
Immune mediated inflammatory diseases
description Chronic immunosuppression is a known risk factor for tuberculosis. Our aim was to reach a consensus on screening and prevention of tuberculosis in patients with immune mediated inflammatory diseases who are candidates to biologic therapy. Methods: Critical appraisal of the literature and expert opinion on immunosuppressive therapies and risk of tuberculosis. Results and conclusion: The currently recommended method for screening is the tuberculin skin test and the interferon gamma assay, after exclusion of active tuberculosis. Positively screened patients should be treated for latent tuberculosis infection. Patients may start biological therapy after 1-2 months, as long as they are strictly adhering to and tolerating their preventive regimen.
publishDate 2012
dc.date.none.fl_str_mv 2012-11-01
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/report
format report
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-81782012000600005
url http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-81782012000600005
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-81782012000600005
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Portuguesa de Gastrenterologia
publisher.none.fl_str_mv Sociedade Portuguesa de Gastrenterologia
dc.source.none.fl_str_mv Jornal Português de Gastrenterologia v.19 n.6 2012
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799137299397607424

Registros relacionados